FDA
-
-
-
-
-
-
-
Moleculin CEO discusses early MIRACLE trial data in investor segment
-
-
-
-
-
-
-
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
-
-
-
-
-
-
-
Moleculin's Annamycin shows no significant heart toxicity in leukemia study
-
-
-
-
-
-
-
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
-
-
-
-
-
-
-
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
-
-
-
-
-
-
-
Moleculin reports 40% response rate in leukemia drug trial
-
-
-
-
-
-
-
Moleculin reports no cardiotoxicity in 90 Annamycin trial subjects
-
330,199 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

